Pyridone A2R antagonists

1. A compound represented by Formula (I)

or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein,

G 1 is N or CR 3a ;

G 2 is N or CR 3b ;

R 3a and R 3b are each independently H or C 1-3 alkyl;

R 1a and R 1b are each independently selected from the group consisting of

i) H,

ii) C 1-8 alkyl optionally substituted with from 1-3 R 5 substituents,

iii) —X 1 —O—C 1-8 alkyl optionally substituted with from 1-3 R 5 substituents,

iv) —C(O)—R 6 ,

v) Y optionally substituted with 1-3 R 7 substituents,

vi) —X 1 —Y optionally substituted with 1-3 R 7 substituents; and

vii)R 1a and R 1b together with the nitrogen to which they are attached form a 5-6 membered heterocycloalkyl ring optionally substituted with from 1-3 R 8 substituents, wherein the heterocycloalkyl has 0-2 additional heteroatom ring vertices selected from the group consisting of O, N, and S;

each Y is C 3-8 cycloalkyl or 4 to 6-membered heterocycloalkyl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S;

R 2 and R 4 are each independently H or C 1-3 alkyl;

each X 1 is C 1-6 alkylene;

each R 5 is independently selected from the group consisting of hydroxyl, C 3-8 cycloalkyl, phenyl, —O-phenyl, —C(O)OR a , and oxo;

each R 6 is C 1-8 alkyl or Y, each of which is optionally substituted with 1-3 substituents selected from the group consisting of hydroxyl, —O-phenyl, phenyl, and —O—C 1-8 alkyl;

each R 7 is independently selected from the group consisting of C 1-8 alkyl, hydroxyl, —O—C 1-8 alkyl, oxo, and —C(O)OR a ;

each R 8 is independently selected from the group consisting of C 1-8 alkyl, hydroxyl, and oxo;

the subscript n is 0, 1, 2 or 3;

each R 9 is independently selected from the group consisting of C 1-8 alkyl, —O—C 1-8 alkyl, —X 1 —O—C 1-8 alkyl, —O—X 1 —O—C 1-8 alkyl, —X 1 —O—X 1 —O—C 1-8 alkyl, —C(O)OR a , halogen, cyano, —NR b R c , Y, —X 1 —C 3-8 cycloalkyl, and —X 2 —Z, wherein X 2 is selected from the group consisting of C 1-6 alkylene, —C 1-6 alkylene-O—, —C 1-4 alkylene-O—C 1-4 alkylene-, —C(O)—, and —S(O) 2 —, Z is 4 to 6-membered heterocycloalkyl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, and wherein each of said R 9 substituents is optionally substituted with 1-3 R 11 ;

each of R 10a , R 10b , R 10c , and R 10d is independently selected from the group consisting of H, C 1-8 alkyl, halo, cyano, —O—C 1-8 alkyl, —X 1 —O—C 1-8 alkyl, —O—X 1 —O—C 1-8 alkyl, —S(O) 2 —C 1-6 alkyl, —C(O)NR d R c , and 4-6-membered heteroaryl having from 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, wherein each of said R 10a-d substituents is optionally substituted with 1-3 R 12 , or two of R 10a , R 10b , R 10c and R 10d on adjacent ring vertices are optionally combined to form a 5-membered heterocyclic ring optionally substituted with 1-2 halogens;

each R 11 is independently selected from the group consisting of hydroxyl, oxo, halo, cyano, —NR d R e , —C(O)OR a , phenyl, C 3-8 cycloalkyl, and C 1-4 alkyl optionally substituted with —C(O)OR a ;

each R 12 is independently selected from the group consisting of halo, cyano, hydroxy, and —C(O)OR a ;

each R a is H or C 1-6 alkyl;

each R b and R c are independently selected from the group consisting of H, C 1-8 alkyl, —S(O) 2 —C 1-6 alkyl, —C(O)OR a , and —X 1 —C(O)OR a ; and

each R d and R e are independently selected from the group consisting of H, C 1-8 alkyl, and —S(O) 2 —C 1-6 alkyl.

2. The compound of claim 1 , having Formula (Ia):

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

3. The compound of claim 1 , having Formula (Ib):

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

4. The compound of claim 1 , wherein at least one of R 10a , R 10b and R 1c is methoxy.

5. The compound claim 1 , having Formula (Ic):

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

6. The compound of claim 1 , having Formula (Id):

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

7. The compound of claim 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein each R 9 is independently selected from the group consisting of C 1-8 alkyl, —O—C 1-8 alkyl, —X 1 —O—C 1-8 alkyl, —O—X 1 —O—C 1-8 alkyl, and —X 1 —O—X 1 —O—C 1-8 alkyl, wherein each of said R 9 substituents is optionally substituted with 1-3 R 11 .

8. The compound of claim 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein each R 9 is independently selected from the group consisting of —C(O)OR a , —NR b R c , Y, —X 1 —C 3-8 cycloalkyl, and —X 2 —Z, wherein X 2 is selected from the group consisting of C 1-6 alkylene, —C 1-6 alkylene-O—, —C(O)—, and —S(O) 2 —, Z is 4 to 6-membered heterocycloalkyl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, and wherein each of said R 9 substituents is optionally substituted with 1-3 R 11 .

9. The compound of claim 1 , having Formula (Ie):

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

10. The compound of claim 1 , having Formula (If):

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

11. The compound of claim 1 , having Formula (Ig):

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

12. The compound of claim 1 , having Formula (Ih):

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

13. The compound of claim 1 , having Formula (Ii):

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

14. The compound of claim 1 , selected from the group consisting of:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

15. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

16. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

17. A method of treating a disease, disorder, or condition, mediated at least in part by the adenosine A 2A receptor (A 2A R), or the adenosine A 2B receptor (A 2B R), or the A 2A R receptor and the A 2B R receptor, said method comprising administering a therapeutically acceptable amount of a compound of claim 1 to a subject in need thereof.

18. The method of claim 17 , wherein said disease, disorder, or condition is cancer.

19. The method of claim 18 , wherein said cancer is a cancer of the prostate, colon, rectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin, mesothelial lining, white blood cell, esophagus, breast, muscle, connective tissue, lung, adrenal gland, thyroid, kidney, or bone; or is glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, or testicular seminoma.

20. The method of claim 18 , wherein said cancer is selected from the group consisting of melanoma, colorectal cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, a brain tumor, lymphoma, ovarian cancer, Kaposi's sarcoma, squamous cell carcinoma of the head and neck, bladder cancer, endometrial cancer, Merkel cell carcinoma, and gastroesophageal cancer.

21. A method of treating cancer in a subject, said method comprising administering to said subject an effective amount of a compound of claim 1 and at least one additional therapeutic agent.

22. The method in accordance with claim 21 , wherein the at least one additional therapeutic agent is a chemotherapeutic agent, an immune-modulating agent, an inflammation-modulating agent, an immune- and inflammation-modulating agent, an anti-hypercholesterolemia agent, an anti-infective agent, or radiation.

23. The method in accordance with claim 21 , wherein the at least one additional therapeutic agent is an immune checkpoint inhibitor, wherein said immune checkpoint inhibitor blocks the activity of at least one of PD1, PDL1, BTLA, LAG3, TIM-3, TIGIT, a B7 family member, or CTLA4.

24. The method in accordance with claim 23 , further comprising a chemotherapeutic agent.

25. The method in accordance with claim 5 , wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, doxorubicin, and pemetrexed.